The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.
about
Targeting the TAM Receptors in LeukemiaMechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment.Irf8 regulates the progression of myeloproliferative neoplasm-like syndrome via Mertk signaling in zebrafish.UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models.MerTK as a therapeutic target in glioblastoma.
P2860
The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
The MERTK/FLT3 inhibitor MRX-2 ...... ons in acute myeloid leukemia.
@en
type
label
The MERTK/FLT3 inhibitor MRX-2 ...... ons in acute myeloid leukemia.
@en
prefLabel
The MERTK/FLT3 inhibitor MRX-2 ...... ons in acute myeloid leukemia.
@en
P2093
P2860
P1433
P1476
The MERTK/FLT3 inhibitor MRX-2 ...... ons in acute myeloid leukemia.
@en
P2093
Catherine C Smith
Clara Libbrecht
Craig T Jordan
Deborah DeRyckere
Dmitri Kireev
Douglas K Graham
Elisabeth A Lasater
Gregory D Kirkpatrick
H Shelton Earp
Katherine A Minson
P2860
P304
P356
10.1172/JCI.INSIGHT.85630
P577
2016-03-01T00:00:00Z